World News: 13:30 GMT Monday 11th February 2019. [Avalon GloboCare Corp. via Globe Newswire via SPi World News]
“Identification and isolation of tissue-specific exosomes is considered by many as the “Holy Grail” in this area,” stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare. “This discovery is essential for future development of endothelial cell-derived angiogenic exosomes in treating ischemic vascular diseases, as well as contribution to tissue and organ regeneration,” added Dr. Jin.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to advancing cell-based technologies and therapeutics, with a focus on developing and empowering innovative and transformative cell-based technologies and their clinical applications. In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth, development, as well as competitiveness in both the domestic and global healthcare markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics, cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.
Globe Newswire: 13:30 GMT Monday 11th February 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.